Our laboratory focuses on using stem cells as a tool to study human lung biology in health and disease and as a potential therapeutic/diagnostic approach for patients with lung diseases. We use patient-derived induced pluripotent stem cells (iPSCs) to generate models of lung disease, such as cystic fibrosis (CF), idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and ciliopathies. We combine state-of-the-art gene editing (CRISPR) and iPSC technologies with directed differentiation, proteomics, epigenetics and next-generation sequencing to: 1) generate reproducible models of respiratory diseases in a dish; 2) generate chimeric animal models to understand disease development and progression; and 3) utilize these models in high-throughput screening.
- Amy Firth named finalist for the British Council’s 2017 Alumni Awards February 17, 2017
- What I’m reading: Amy Firth shares a top pick January 10, 2017
- Amy Firth joins editorial board of the American Journal of Physiology: Cell Physiology December 21, 2016